1
|
Olliaro P, Bourner J, Boum II Y, Nakouné E, Pesonel E, Rojek A, Yazdanpanah Y, Lescure FX, Calmy A, Grinsztejn B, Horby P, Merson L, Dunning J. Mpox: The alarm went off. Have we gone back to sleep? PLoS Negl Trop Dis 2024; 18:e0011871. [PMID: 38236842 PMCID: PMC10796058 DOI: 10.1371/journal.pntd.0011871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2024] Open
Affiliation(s)
- Piero Olliaro
- International Severe Acute Respiratory and emerging Infection Consortium (ISARIC), Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom
| | - Josephine Bourner
- International Severe Acute Respiratory and emerging Infection Consortium (ISARIC), Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom
| | - Yap Boum II
- Institut Pasteur de Bangui, Bangui, Central African Republic
| | | | - Elise Pesonel
- International Severe Acute Respiratory and emerging Infection Consortium (ISARIC), Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom
| | - Amanda Rojek
- International Severe Acute Respiratory and emerging Infection Consortium (ISARIC), Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom
| | | | - François-Xavier Lescure
- Infectious diseases department, Bichat hospital, APHP, Paris Cité University, IAME UMRS 1137 Inserm, Paris, France
| | | | - Beatriz Grinsztejn
- Instituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brazil
| | - Peter Horby
- International Severe Acute Respiratory and emerging Infection Consortium (ISARIC), Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom
| | - Laura Merson
- International Severe Acute Respiratory and emerging Infection Consortium (ISARIC), Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom
| | - Jake Dunning
- International Severe Acute Respiratory and emerging Infection Consortium (ISARIC), Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom
| |
Collapse
|
2
|
Pesonel E, Hoffmann I, Guiraud L, Bourner J, Diallo A, Dunning J, Horby P, Kali S, Laouénan C, Mentré F, Merson L, Molino D, Palich R, Rojek A, Tacconelli E, Tardivon C, Yazdanpanah Y, Calmy A, Lescure FX, Olliaro P. MOSAIC: A cohort study of human mpox virus disease. Wellcome Open Res 2023; 8:415. [PMID: 38031544 PMCID: PMC10685065 DOI: 10.12688/wellcomeopenres.19616.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/23/2023] [Indexed: 12/01/2023] Open
Abstract
Background Human mpox is a viral disease caused by an Orthopoxvirus, human mpox virus (hMPXV), typically causing fever and a rash. Mpox has historically been endemic to parts of Central and West Africa, with small numbers of imported cases reported elsewhere, but starting May 2022 an unprecedented global outbreak caused by clade IIb hMPXV was reported outside traditionally endemic countries. This prompted the initiation of MOSAIC, a cohort study implemented in Europe and Asia that aims to describe clinical and virologic outcomes of PCR-confirmed hMPXV disease, including those who receive antiviral therapy. The study is ongoing. Methods MOSAIC recruits participants of any age with laboratory-confirmed mpox disease who provide informed consent. Participants enrol in the cohort for a total of six months. Blood, lesion and throat samples are collected at several timepoints from the day of diagnosis or the first day of treatment (Day 1) until Day 28 for PCR detection of hMPXV. Clinical data are collected by clinicians and participants ( via a self-completion questionnaire) for six months to characterize the signs and symptoms associated with the illness, as well as short- and more long-term outcomes. Discussion The design and prompt implementation of clinical research response is key in addressing emerging outbreaks. MOSAIC began enrolment within two months of the start of the international mpox epidemic. While the number of cases is now low, the study remains open for inclusion. ICTRP registration EU CT number: 2022-501132-42-00 (22/06/2022).
Collapse
Affiliation(s)
- Elise Pesonel
- ISARIC - Pandemic Sciences Institute, University of Oxford, Oxford, UK
| | - Isabelle Hoffmann
- AP-HP. Nord, Hôpital Bichat, Department of Epidemiology Biostatistics and Clinical Research, Paris, France
| | - Laetitia Guiraud
- HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland
| | - Josephine Bourner
- ISARIC - Pandemic Sciences Institute, University of Oxford, Oxford, UK
| | | | - Jake Dunning
- ISARIC - Pandemic Sciences Institute, University of Oxford, Oxford, UK
| | - Peter Horby
- ISARIC - Pandemic Sciences Institute, University of Oxford, Oxford, UK
| | | | - Cédric Laouénan
- AP-HP. Nord, Hôpital Bichat, Department of Epidemiology Biostatistics and Clinical Research, Paris, France
- Université Paris Cité, INSERM, IAME UMR 1137, Paris, France
| | - France Mentré
- AP-HP. Nord, Hôpital Bichat, Department of Epidemiology Biostatistics and Clinical Research, Paris, France
- Université Paris Cité, INSERM, IAME UMR 1137, Paris, France
| | - Laura Merson
- ISARIC - Pandemic Sciences Institute, University of Oxford, Oxford, UK
| | | | - Romain Palich
- Sorbonne University, Infectious Diseases department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM U1136, Paris, France
| | - Amanda Rojek
- ISARIC - Pandemic Sciences Institute, University of Oxford, Oxford, UK
| | | | - Coralie Tardivon
- AP-HP. Nord, Hôpital Bichat, Department of Epidemiology Biostatistics and Clinical Research, Paris, France
| | - MOSAIC study group
- ISARIC - Pandemic Sciences Institute, University of Oxford, Oxford, UK
- AP-HP. Nord, Hôpital Bichat, Department of Epidemiology Biostatistics and Clinical Research, Paris, France
- HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland
- INSERM-ANRS| MIE, France, Paris, France
- Université Paris Cité, INSERM, IAME UMR 1137, Paris, France
- Sorbonne University, Infectious Diseases department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM U1136, Paris, France
- University of Verona, Verona, Italy
- AP-HP Nord, Hôpital Bichat, Department of Infectious and Tropical Diseases, Paris, France
| | - Yazdan Yazdanpanah
- INSERM-ANRS| MIE, France, Paris, France
- AP-HP Nord, Hôpital Bichat, Department of Infectious and Tropical Diseases, Paris, France
| | - Alexandra Calmy
- HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland
| | - F-Xavier Lescure
- Université Paris Cité, INSERM, IAME UMR 1137, Paris, France
- AP-HP Nord, Hôpital Bichat, Department of Infectious and Tropical Diseases, Paris, France
| | - Piero Olliaro
- ISARIC - Pandemic Sciences Institute, University of Oxford, Oxford, UK
| |
Collapse
|